UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2019
Commission File Number: 001-38097
ARGENX SE
(Translation of registrants name into English)
Willemstraat 5
4811 AH, Breda, the Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
argenx SE
On May 7, 2019, argenx SE (the Company ) issued a press release and the voting results from its Annual General Meeting of Shareholders held on May 7, 2019, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including the exhibits hereto, is incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-225370) and S-8 (File No. 333-225375) .
EXHIBITS
Exhibit |
|
Description |
|
|
|
99.1 |
|
Press Release dated May 7, 2019 |
|
|
|
99.2 |
|
Voting Results from the Annual General Meeting of Shareholders held on May 7, 2019 |
argenx announces results of Annual General Meeting of Shareholders
May 7, 2019
Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the proposed resolutions presented at our Annual General Meeting of Shareholders were duly passed at the meeting, which was held today at 10:00 a.m. CET.
As part of the approved resolutions:
· Don deBethizy has been re-appointed as a non-executive director to the board of directors;
· Deloitte Accountants B.V. has been appointed as our external auditor for the 2019 financial year; and
· the board of directors has been authorized to issue shares up to a maximum of 20% of the outstanding share capital and to limit or exclude pre-emptive rights.
Based on initial shareholder feedback the board of directors has decided to withdraw the proposed new option plan for further consideration. Until the new stock option plan and the renewal of the specific authorization to issue shares and rights to shares under this option plan have been accepted by a next general shareholders meeting, argenx will rely on the existing option plan (as approved on May 8, 2018) to issue options to key persons.
The results of the votes will be posted shortly on our website.
All documents relating to the shareholders meeting can be consulted on our website: www.argenx.com
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenxs ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE Antibody TM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.
www.argenx.com
For further information, please contact:
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Beth DelGiacco, Vice President, Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should and include statements argenx makes concerning its annual meeting and related plans and the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenxs actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenxs expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenxs reliance on collaborations with third parties; estimating the commercial potential of argenxs product candidates; argenxs ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenxs limited operating history; and argenxs ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenxs U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenxs most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Annual general meeting of argenx SE 7 May 2019 Voting results
Total number of outstanding shares at the record date. |
|
37,616,142 |
|
Total shares present or represented at the AGM. |
|
26,890,219 |
|
Percentage represented share capital at AGM. |
|
71.49 |
% |
Total valid votes at AGM. |
|
26,890,219 |
|
|
|
|
||||
10 |
|
Appointment of Deloitte Accountants B.V. as external auditor of argenx SE for the 2019 financial year. |
||||
|
|
|
||||
|
Total shares voted |
|
26,890,219 |
|
|
|
|
Represented share capital |
|
71.49 |
% |
|
|
|
Votes for |
|
26,847,854 |
|
|
|
|
Votes against |
|
0 |
|
|
|
|
Abstained |
|
42,365 |
|
|